glp-1 risk factors of pancreatic cancer associated with receptor agonist therapy SGLTi and GLP-1 in HF

This comes as the American College of Cardiology (ACC) released its five top trends in cardiovascular medicine in 2025, including Anti-Obesity Drugs: Cardiovascular Benefit Beyond Weight Loss. The ACC reports that semaglutide and tirzepatide both demonstrate remarkable cardiovascular benefits that extend beyond weight management. Clinical trials show these medications can reduce the risk of major adverse cardiovascular events by up to 20% in patients with obesity and preexisting cardiovascular conditions

Many researchers find their optimal dose between 7.5 mg and 10 mg

Calcification: The formation of calcium deposits as fibroid tissue dies off may lead to a hardened, non-functioning fibroid

Excess weight is the strongest modifiable risk factor, fat deposits around the upper airway narrow the breathing passage, and abdominal fat reduces lung volume

These molecules are peptides or short chains of amino acids that form the building blocks of proteins

Reference intervals in Danish children and adolescents for bone turnover markers carboxy-terminal cross-linked telopeptide of type I collagen (-CTX), pro-collagen type I N-terminal propeptide (PINP), osteocalcin (OC) and bone-specific alkaline phosphatase (bone ALP)